[go: up one dir, main page]

AR061055A1 - HEMICITRATE SALT OF 2,3-DICLORO-N-CICLOPENTIL-N - ((3S) -PIRROLIDIN-3-IL) BENZAMIDA - Google Patents

HEMICITRATE SALT OF 2,3-DICLORO-N-CICLOPENTIL-N - ((3S) -PIRROLIDIN-3-IL) BENZAMIDA

Info

Publication number
AR061055A1
AR061055A1 ARP070102190A ARP070102190A AR061055A1 AR 061055 A1 AR061055 A1 AR 061055A1 AR P070102190 A ARP070102190 A AR P070102190A AR P070102190 A ARP070102190 A AR P070102190A AR 061055 A1 AR061055 A1 AR 061055A1
Authority
AR
Argentina
Prior art keywords
ciclopentil
benzamida
pirrolidin
dicloro
hemicitrate
Prior art date
Application number
ARP070102190A
Other languages
Spanish (es)
Inventor
Florian Wakenhut
Paul Vincent Fish
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AR061055A1 publication Critical patent/AR061055A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe una sal farmacéuticamente y veterinariamente aceptable mejorada de 2,3-dicloro-N-ciclopentil-N-[(3S)-pirrolidin-3-iI]benzamida y composiciones de la misma. Reivindicacion 1: Hemicitrato de 2,3-dicloro-N-ciclopentil-N-[(3S)-pirrolidin-3- il]benzamida. Reivindicacion 2: Un compuesto de acuerdo con la reivindicacion 1 caracterizado por un patron de difraccion de rayos X en polvo (PXRD) el cual muestra picos principales a 12,9, 15,0, 15,2, 18,4 y 20,0 grados 2theta+- 0,1° cuando se mide usando radiacion CuKalfa (longitud de Á).An improved pharmaceutically and veterinarily acceptable salt of 2,3-dichloro-N-cyclopentyl-N - [(3S) -pyrrolidin-3-i] benzamide and compositions thereof is described. Claim 1: 2,3-Dichloro-N-cyclopentyl-N - [(3S) -pyrrolidin-3-yl] benzamide hemicitrate. Claim 2: A compound according to claim 1 characterized by a powder X-ray diffraction pattern (PXRD) which shows major peaks at 12.9, 15.0, 15.2, 18.4 and 20.0 2theta degrees + - 0.1 ° when measured using CuKalfa radiation (wavelength = 1.5406 Á).

ARP070102190A 2006-05-22 2007-05-21 HEMICITRATE SALT OF 2,3-DICLORO-N-CICLOPENTIL-N - ((3S) -PIRROLIDIN-3-IL) BENZAMIDA AR061055A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74787706P 2006-05-22 2006-05-22

Publications (1)

Publication Number Publication Date
AR061055A1 true AR061055A1 (en) 2008-07-30

Family

ID=38723668

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102190A AR061055A1 (en) 2006-05-22 2007-05-21 HEMICITRATE SALT OF 2,3-DICLORO-N-CICLOPENTIL-N - ((3S) -PIRROLIDIN-3-IL) BENZAMIDA

Country Status (4)

Country Link
JP (1) JP2007314534A (en)
AR (1) AR061055A1 (en)
TW (1) TW200815341A (en)
WO (1) WO2007135530A2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1638933T1 (en) * 2003-06-17 2008-10-31 Pfizer N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
GB0314054D0 (en) * 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors

Also Published As

Publication number Publication date
WO2007135530A3 (en) 2008-03-27
JP2007314534A (en) 2007-12-06
TW200815341A (en) 2008-04-01
WO2007135530A2 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
ES2539430T3 (en) Metastine derivatives and use thereof
PT2404906E (en) Methods of synthesizing pharmaceutical salts of a factor xa inhibitor
EA200801341A1 (en) CONDENSED BICYCLIC INHIBITORS mTOR
EA200801381A1 (en) DERIVATIVES OF PYRIMIDINE
ATE506354T1 (en) SUBSTITUTED ARYLCYCLOPROPYLACETAMIDE AS GLUCOCINASE ACTIVATORS
CY1105994T1 (en) ARRANGEMENT PENTANOLS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS
DK1529044T5 (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
WO2007076348A3 (en) Azaindole inhibitors of aurora kinases
WO2007029035A3 (en) Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors
CR8827A (en) FUSED HETEROCICLIC COMPOUND
CY1105826T1 (en) METHOD FOR THE SYNTHESIS OF (1S)-4,5-DIMETHOXY-1-(METHYLAMINOMETHYL)BENZOCYCLOBUTANE AND ITS ADDITION SALTS AND APPLICATION TO THE SYNTHESIS OF IVABRADINE AND ITS ADDITION SALTS WITH A PHARMACEUTICALLY ACCEPTABLE ACID
EA200601274A1 (en) NEW CRYSTAL FORM III OF AGOMELATIN, THE METHOD OF ITS OBTAINING AND PHARMACEUTICAL COMPOSITIONS THAT HERE CONTAINS
EA200970669A1 (en) DERIVATIVES 2-AMINO-5,7-DIHYDRO-6N-PYRROLO [3,4-D] Pyrimidine as HSP-90 inhibitors intended for cancer
EA200970124A1 (en) DERIVATIVES 2-ARILINDOL AS NPGES-1 INHIBITORS
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
EA200970373A1 (en) ANTIDEPRESSANT, NEUROPROTECTOR, β-AMYLOID DEPOSIT INHIBITOR OR AGENT REDUCING AGENT, CONTAINING HETEROCYCLIC COMPOUND
DE60319080D1 (en) PHENYLOXYALKANIC DERIVATIVES AS HPPAR ACTIVATORE
DK2016051T3 (en) Beta-crystalline form of perindoprilarginine salt, process for its preparation and pharmaceutical compositions containing this
DE602005019316D1 (en) Aromatische etherderivate als thrombin-hemmer
AR049681A1 (en) MACROLIDS PREPARED FROM ACTINOMICETS. PHARMACEUTICAL COMPOSITIONS
WO2008068610A3 (en) Photoactive compounds
DOP2011000154A (en) 3-AMINOCICLOPENTANCARBOXAMIDAS
EP1906238A3 (en) Photosensitive composition and pattern forming method using the same
AR061055A1 (en) HEMICITRATE SALT OF 2,3-DICLORO-N-CICLOPENTIL-N - ((3S) -PIRROLIDIN-3-IL) BENZAMIDA
WO2007017728A3 (en) Novel heterocyclic compounds

Legal Events

Date Code Title Description
FB Suspension of granting procedure